ClinicalTrials.gg
RecruitingNCT06780241Updated Jan 2, 2026

Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease

An observational study in Aortic Regurgitation, Mitral Regurgitation and Aortic Stenosis, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by The Cleveland Clinic · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Aortic Valve Insufficiency with a site in United States — 7 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · United States.

Planned enrollment
7th of 17
200 · median 200
Started
2024
with 2 others
Observational
17 of 41
4 open now
Primary completion
2030-12
later than 15 of 16 live
Registered
39th of 41
by date
Lead sponsor
5 of 41
The Cleveland Clinic

Among the 41 studies in Aortic Valve Insufficiency with a site in United States, this one is the 7th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2024, is one of 17 observational ones, reaches primary completion later than 15 of the 16 other live ones, and was the 39th registered.

Aortic Valve Insufficiency

170 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

Browse Aortic Valve Insufficiency studies →

Open to participants now

7 of the 41 studies in Aortic Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Aortic Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This project aims to validate sex-specific biologic signatures associated with aortic valve disease developed in a large multicenter CMR registry, using unsupervised phenomapping.

The aim to use standard and advanced CMR techniques (MRF, DTI, chemical exchange transfer, and radiomics analysis) is to determine advanced CMR predictors of reverse remodeling following aortic valve surgery and develop sex-specific thresholds for risk. Infrastructure developed by this study will enable development of an innovative, scalable, sex-specific precision medicine cardiovascular imaging pipeline to determine overall risk and treatment response.

Read the detailed description

Chronic valvular heart disease leads to significant left ventricular (LV) remodeling. Current national guidelines for surgical/procedural referral for valvular heart disease do not consider sex differences in presence of symptoms, LV remodeling and dysfunction. However, our prior research in patients with chronic aortic regurgitation, validated by our recent multicenter study, demonstrated that despite higher left ventricular function, and less ventricular dilation, females experienced more heart failure symptoms, fewer referrals for surgical intervention, and higher prevalence of adverse outcomes compared to males. Similarly, published HVTI data have demonstrated increased adverse outcomes in women referred for surgical mitral valve intervention.

Cardiac magnetic resonance (CMR) provides an exciting opportunity to characterize sex differences in LV remodeling.In combination with conventional CMR measures, novel CMR techniques such as Magnetic Resonance Fingerprinting (MRF), Diffusion Tensor imaging (DTI) and radiomics analysis provide tissue level specificity with potential to enhance phenomapping.

Limitations in understanding sex-specific remodeling patterns stem from heterogeneity of presentation, which confound traditional analytic methods. Phenomapping, a method of machine learning, clusters imaging features and patients into distinct phenotypic groups. Unsupervised phenomapping enables unbiased grouping of patients by both clinical characteristics as well as complex imaging features. In recent studies, this unbiased phenomapping approach demonstrates superior risk stratification of cardiac disease compared to traditional approaches that can be used to guide individualized treatment

The aim to use advanced CMR techniques (MRF, DTI, chemical exchange transfer, and radiomics analysis) is to determine advanced CMR predictors of reverse remodeling following procedural valve intervention and develop sex-specific thresholds for risk. Results from this study would enable the development of sex-specific precision medicine pathway, augmented by advanced imaging features, to better predict overall risk and treatment response, and thus enable novel patient selection criteria.

Study hypothesis: Radiomics, MRF, chemical exchange transfer, and DTI will elucidate distinct sex-specific biologic signatures, in addition to standard CMR imaging features, and are associated with adverse outcomes, and reverse remodeling following surgical/procedural valve intervention.

03

Conditions studied

  • Aortic Regurgitation
  • Mitral Regurgitation
  • Aortic Stenosis
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with at least moderate Aortic Stenosis or Aortic Regurgitation who are scheduled for a surgical repair or replacement of their aortic valve.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-90 years of age
  • Suspected moderate or severe (2-3+ or more) aortic regurgitation, or moderate or more aortic stenosis on the basis of prior known clinical history, echocardiogram or cardiac MRI.

Exclusion criteria

Exclusion Criteria:

  • Acute traumatic cardiac injury
  • Aortic dissection or aortic root rupture
  • Congenital heart diseases such as patent ductus arteriosus, coarctation of aorta, ASD and VSD
  • Presence of A-V fistula or intracardiac shunts
  • Any to cardiac MRI including:

    • Patients with any MR-incompatible implant, including cardiac pacemakers or defibrillators, or older types of cerebral aneurysm clips.
    • Patients who weigh more than 440 lbs. or have a very wide waist circumference.
    • Patients with claustrophobia may have difficulty tolerating the exam.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intervention

    Cardiac MRI (CMR) with Magnetic Resonance Fingerprinting (MRF), fSENC (a new CMR technology which may detect subclinical signs of myocardial damage by measuring myocardial strain), Diffusion Tensor imaging (DTI), and chemical exchange transfer imaging with contrast at baseline and without contrast at follow up. Rapid Assessment of Physical Activity questionnaire Kansas City Cardiomyopathy Questionnaire

    Diagnostic Test: CMR · Other: Quality of Life Questionnaire

Interventions

  • Diagnostic testCMR

    CMR (with contrast at baseline and non-contrast at follow-up)

  • OtherQuality of Life Questionnaire

    Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire

06

What researchers measure

Primary outcomes

  1. Change in LV Dilation and/or change in LVEF

    Significant change in LV remodeling will be defined as a change in EF by 10 units (reverse remodeling is defined at least 10 unit decrease) or change in LV end-diastolic/systolic volume by 10% (Reverse remodeling is defined as at least decrease in LV end-diastolic/systolic volume by 10%

    Time frame: 6-12 months

Secondary outcomes

  1. Change in Aortic Regurgiation

    Change in Aortic Regurgitant Fraction will be modeled as a continuous variable, as well as a threshold change of 5 points or more, as measured by cardiac MRI

    Time frame: 6-12 months

  2. Change in BNP

    NT-proBNP will be modeled as a continuous variable as well as a threshold change of 30% or decrease to level \< 1000

    Time frame: 6-12 months

  3. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score

    KCCQ will be modeled as a continuous variable, as well as a threshold change of 5 points or more. KCCQ scoring transforms Likert-scale answers into 0-100 scores (higher is better) for domains like Physical Limitation, Symptom Frequency, Quality of Life, and Social Limitations, with a summary score reflecting overall health, where 0-24 is very poor, 25-49 poor/fair, 50-74 fair/good, and 75-100 good/excellent health.

    Time frame: 6-12 months

  4. 6 minute walk test

    6 minute walk test will be modeled as a continuous variable as well as a threshold change of 30meters or more

    Time frame: 6-12 months

07

Study locations

1 of 1 sites recruiting
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • Degorah Kwon, MD · Contact216-444-8526
    • Lydia DeAngelo · Contactdeangel2@ccf.org · 401-225-1929
    • Xiaofeng Wang, PhD · Sub investigator
    • Christopher Nguyen, PhD · Sub investigator
    • Eric Roselli, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2030, 72 months after the start.

Of 35 observational studies under Aortic Valve Insufficiency, half reached primary completion within 86 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 132. This study's planned 72 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Dec 10, 2024
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06780241
Responsible party
Deborah Kwon, MD (Principal Investigator, The Cleveland Clinic) — Principal investigator
First posted
Jan 17, 2025
Start date
Dec 10, 2024
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jan 2, 2026

Study contacts

Deborah Kwon, MD
Contact
kwond@ccf.org
216-444-8526
Deborah Kwon, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion